Transarterial Chemoembolization, Transarterial Chemotherapy, and Intra-arterial Chemotherapy for Hepatocellular Carcinoma Treatment

Seminars in Oncology

Volumn 37, Issue 2, 2010, Pages 89-93

  Tsochatzis, Emmanuel A ^a   Germani, Giacomo ^a   Burroughs, Andrew K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; GELFOAM; IODINATED POPPYSEED OIL; POLYVINYL ALCOHOL; SORAFENIB; VASCULOTROPIN;

ABDOMINAL PAIN; ANTIANGIOGENIC THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG TARGETING; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERMETHOD COMPARISON; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; NONSURGICAL INVASIVE THERAPY; PERCUTANEOUS ETHANOL INJECTION THERAPY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TRANSARTERIAL RADIOEMBOLIZATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS;

EID: 77952349768     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.03.007     Document Type: Article

References (41)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
3. Pleguezuelo M., Germani G., Marelli L., et al. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2 (2008) 761-784
4. Llovet J.M., Fuster J., and Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant 10 (2004) S115-S120
5. Brown D.B., Gould J.E., Gervais D.A., et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 20 (2009) S425-S434
6. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
7. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
8. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
9. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective?. A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30 (2007) 6-25
10. Giannini E.G., Bodini G., Corbo M., et al. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 31 (2010) 493-501
11. Kasugai H., Kojima J., Tatsuta M., et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 97 (1989) 965-971
12. Lu W., Li Y., He X., and Chen Y. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Hepatogastroenterology 50 (2003) 2079-2083
13. Bhattacharya S., Novell J.R., Winslet M.C., and Hobbs K.E. Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg 81 (1994) 1563-1571
14. Coldwell D.M., Stokes K.R., and Yakes W.F. Embolotherapy: agents, clinical applications, and techniques. Radiographics 14 (1994) 623-643
15. Brown D.B., Pilgram T.K., Darcy M.D., et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 16 (2005) 1661-1666
16. Poon R.T., Tso W.K., Pang R.W., et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5 (2007) 1100-1108
17. Varela M., Real M.I., Burrel M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46 (2007) 474-481
18. Kettenbach J., Stadler A., Katzler I.V., et al. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31 (2008) 468-476
19. Tsochatzis E., Meyer T., Marelli L., and Burroughs A. Which transarterial therapy is best for hepatocellular carcinoma?-The evidence to date. J Hepatol (2010) 10.1016/j.jhep.2010.01.031 Epub ahead of print
20. Sergio A., Cristofori C., Cardin R., et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103 (2008) 914-921
21. Chang J.M., Tzeng W.S., Pan H.B., Yang C.F., and Lai K.H. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 74 (1994) 2449-2453
22. Kawai S., Okamura J., Ogawa M., et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma-a comparison of lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 31 Suppl (1992) S1-S6
23. Malagari K., Pomoni M., Kelekis A., et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol (2009)
24. Burroughs A., Hochhauser D., and Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 5 (2004) 409-418
25. Maeda S., Fujiyama S., Tanaka M., Ashihara H., Hirata R., and Tomita K. Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. Hepatol Res 23 (2002) 202-210
26. Okusaka T., Kasugai H., Shioyama Y., et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol 51 (2009) 1030-1036
27. Forner A., and Trinchet J.C. Transarterial therapies in HCC: does embolization increase survival?. J Hepatol 51 (2009) 981-983
28. Lammer J., Malagari K., Vogl T., et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33 (2010) 41-52
29. Leung D.A., Goin J.E., Sickles C., Raskay B.J., and Soulen M.C. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 12 (2001) 321-326
30. DeAngelis C.D., and Fontanarosa P.B. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA 301 (2009) 1931
31. Becker G., Soezgen T., Olschewski M., Laubenberger J., Blum H.E., and Allgaier H.P. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 11 (2005) 6104-6109
32. Germani G., Pleguezuelo M., Gurusamy K., Meyer T., Isgro G., and Burroughs A. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. J Hepatol (2010) 10.1016/j.jhep.2009.12.004
33. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
34. Fatourou E.M., and Koskinas J.S. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert Rev Anticancer Ther 9 (2009) 1499-1510
35. von Marschall Z., Cramer T., Hocker M., Finkenzeller G., Wiedenmann B., and Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48 (2001) 87-96
36. Reyes D, Azad N, Kamel IR, et al. Phase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization (DEB-TACE) for patients with hepatocellular carcinoma: interim safety and efficacy analysis. American Association of the Study of Liver Diseases. Boston, MA, November 2009; Late breaker abstract 9.
37. Kulik L.M., Atassi B., van H.L., et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94 (2006) 572-586
38. 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transplant 10 (2004) S107-S110
39. Salem R., Lewandowski R.J., Mulcahy M.F., et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 10.1053/j.gastro.2009.09.006
40. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
41. Stigliano R., Marelli L., Yu D., Davies N., Patch D., and Burroughs A.K. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 33 (2007) 437-447